Access, cost, and policy

This is an updated FDA drug label for tofacitinib, a JAK inhibitor that is approved for ulcerative colitis and other immune conditions.

Based on the title and source metadata, this appears to be a market or business news related to Access, cost, and policy. The original article is from firstwordpharma.com.

If approved, a vedolizumab biosimilar could increase treatment options and potentially lower costs or improve access to an established biologic used for moderate-to-severe Crohn’s disease and ulcerative colitis....

Regulatory review starts a formal approval process that could lead to a lower-cost biosimilar alternative to Entyvio (vedolizumab), potentially improving access to a biologic used in Crohn’s disease and ulcerative...

High out-of-pocket costs and insurance practices can force people with Crohn’s and other chronic autoimmune diseases to delay or stop biologic therapy, which has direct consequences for disease control and quality of...

A vedolizumab biosimilar could increase access to an important biologic treatment for people with moderate‑to‑severe UC and Crohn’s disease by offering a potentially lower‑cost alternative. Regulatory review by the FDA...

Cure8 could only read part of this source from bignewsnetwork.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Access, cost, and policy.

People with both IBD and another immune-mediated disease (psoriatic disease) had more hospital admissions and higher inpatient costs over ten years in this population.

Cure8 could only read part of this source from endpoints.news, so this card uses cautious topic tags instead of a full summary. It is tagged for Risankizumab, IL-23 inhibitor, and Access, cost, and policy.

Patients with IBD receiving biologic therapy need regular lab monitoring, TB screening, vaccinations, and bone-density assessment; many of these services were underused before the dashboard. Tools that improve those...

Market shifts — including more biosimilars, expanding biologic and small-molecule options, and wider online pharmacy access — can affect how quickly and affordably new Crohn’s treatments reach patients. Patients on...

Accepted applications for a vedolizumab biosimilar could lead to another treatment option for adults with moderate‑to‑severe ulcerative colitis and Crohn’s disease and may improve access or affordability if approved.

If approved, a vedolizumab biosimilar could increase access to an established IBD biologic by offering a lower-cost alternative, potentially reducing barriers to starting or continuing treatment for people with...

PROM completion is important for monitoring symptoms and disease control between visits. The study shows a single empowerment campaign produced a short‑term boost in PROM response but not sustained engagement,...

Patients and clinicians managing ulcerative colitis in India may have greater access to an effective oral treatment (tofacitinib) that can reduce steroid dependence and is available as lower-cost generics. This could...

High and rising out-of-pocket costs can force people with Crohn’s disease to worry about medical debt, skip care, or make major life changes. Policy choices about insurance coverage (like Medicaid expansion) can...

A new bispecific antibody program (TL1A x IL-23p19) advancing toward patient trials could expand treatment options for people with ulcerative colitis and Crohn’s disease if later-stage trials confirm safety and efficacy....

If biologic availability, infusion capacity, or therapeutic drug monitoring are limited where you live, oral JAK inhibitors could offer a practical, effective alternative for moderate‑to‑severe IBD, according to this...

Cure8 could only read part of this source from newsbytesapp.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease.

This DailyMed/FDA label update affects adults with moderately to severely active ulcerative colitis because it states approved use of tofacitinib extended‑release and highlights important safety warnings and recommended...

Label updates for INFLECTRA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and safety warnings for a commonly used anti-TNF biologic/biosimilar. The label...

An FDA DailyMed label update directly affects prescribing information and safety warnings for tofacitinib, a drug used in ulcerative colitis and other immune-mediated diseases. Patients and clinicians should be aware of...

For people with IBD who do not respond to standard biologic doses, escalating the dose appears common in routine care and was associated with better short-term remission rates and reduced healthcare use in this registry...

Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...

Early company-reported clinical responses in special-access patients and planned Phase 2 trials could signal a new stem-cell therapy approach advancing for fistulising Crohn’s disease — a complication that can be hard to...

Biosimilars can expand access to effective biologic treatment for people with IBD by reducing costs, but adoption barriers mean some patients may not benefit. Understanding evidence, practical concerns, and...

Patients with IBD may see TREMFYA appearing more widely as a treatment option and influencing which drugs companies prioritize. Rising sales and trial signals can speed access but don’t replace clinical guidance about...

New oral drugs that act mainly in the gut could offer more convenient options and potentially fewer systemic side effects for people with UC or Crohn’s disease. Early clinical signals and a planned Phase 2 trial mean...

Cure8 found this source from m.investing.com, but the page could not be read reliably yet. It is tagged for Access, cost, and policy. Open the original article for the full details.

Transition from pediatric to adult IBD care is a high-risk period; structured programs and better communication can improve adherence and reduce relapse and hospitalization risk for young people with IBD.

Subcutaneous infliximab could offer children with IBD a more convenient dosing route with higher, steadier drug levels while maintaining remission. Insurance and labeling barriers affected access in this US cohort.

This trial tests whether people with UC in deep remission can safely stop JAK inhibitor therapy — potentially reducing long-term exposure and associated safety concerns while preserving disease control and quality of...

Cure8 found this source from fiercepharma.com, but the page could not be read reliably yet. It is tagged for Guselkumab, IL-23 inhibitor, and Access, cost, and policy. Open the original article for the full details.

Cure8 could only read part of this source from theaustralian.com.au, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Access, cost, and...

Changes to aeromedical waiver policy could allow some aviators with well-controlled Crohn’s disease to remain or return to flight duty, affecting careers and military readiness while aiming to preserve safety.

Patients and clinics are still deciding how much care can be done remotely. Knowing who prefers in-person versus remote visits helps tailor care so patients receive the visit type they need and want, and supports...

Standard measures like BMI and routine labs can miss muscle and fat depletion in IBD patients. Better screening plus access to dietitian assessment could find treatable malnutrition that affects recovery and quality of...

Intravenous iron is frequently used in people with IBD who have iron deficiency anaemia. A change in which iron formulation hospitals use could affect healthcare spending and potentially access to treatment.

This is relevant because military aviators with Crohn’s disease have historically been excluded from waivers; policy changes could allow some stable patients to continue flying if objective evidence supports low...

The study shows that more children worldwide are living with early-onset IBD even as mortality has fallen, and it highlights persistent socioeconomic disparities—important for families and clinicians tracking pediatric...

Patients and clinicians choosing first‑line biologic therapy for ulcerative colitis may find evidence here that vedolizumab can provide sustained clinical benefit and a favorable safety profile in a biologic‑naïve...

Avoidable unplanned hospital admissions are common and costly for people with IBD. This study suggests many such admissions stem from healthcare access and service delivery problems—not just disease severity—so system...

Many patients and clinicians are interested in subcutaneous infliximab because it can be more convenient than IV infusions and may change drug exposure.

Accessible, culturally tailored digital education can help close IBD health-literacy gaps in Latin America; improved knowledge may help people better manage care, ask informed questions, and engage with clinicians.

A new DailyMed label update for RINVOQ (upadacitinib) outlines FDA-approved uses that include Crohn’s disease and ulcerative colitis and highlights important safety warnings relevant to people with IBD. Patients and...

The study suggests that a physician-endorsed, librarian-developed information prescription may improve quality of life and reduce short-term relapse in people with IBD, a non-pharmacological approach that could be...

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Research and clinical...

The FDA label update for tofacitinib lists ulcerative colitis among approved uses and highlights serious safety warnings that are directly relevant to people with IBD considering or taking this oral JAK inhibitor.